SOTYKTU® and you

Please read the Patient Information Leaflet (PIL) before taking SOTYKTU.

What is SOTYKTU and what is it used for?

SOTYKTU contains the active substance deucravacitinib, which belongs to a group of medicines called tyrosine kinase 2 (TYK2) inhibitors that help to reduce inflammation associated with psoriasis. SOTYKTU is used to treat adults with moderate to severe “plaque psoriasis”, an inflammatory condition affecting the skin, which can cause red, scaly, thick, itchy, painful patches on your skin and can also affect your scalp and nails, hands, and feet.

What can I expect from treatment with SOTYKTU?

Skin clearance

SOTYKTU could reduce skin plaques and other signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) and symptoms (itch, pain, burning, stinging, and skin tightness) of your psoriasis.

Quality of life

SOTYKTU has also been shown to improve the quality of life in patients with psoriasis.

This means that the impact of your condition on daily activities, relationships and other factors should be less than it was before.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common (may affect more than 1 in 10 people)

upper respiratory tract (nose and throat) infections with symptoms such as sore throat and stuffy nose

Common (may affect up to 1 in 10 people)

viral infection of the mouth (such as cold sores)
an increase in the level of an enzyme in your blood called creatine phosphokinase (CPK)
sores in mouth
acne-like rashes
inflammation of hair follicles

Uncommon (may affect up to 1 in 100 people)

shingles (herpes zoster)

Reporting of side effects

If you get any side effects, talk to your doctor, nurse, or pharmacist. This includes any possible side effects not listed in your patient information leaflet or on this website.

V This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

See www.mhra.gov.uk/yellowcard for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com

Please read the Patient Information Leaflet (PIL) before taking SOTYKTU.

References

SOTYKTU UK Patient Information Leaflet (PIL). July 2023. Available at: https://www.medicines.org.uk/emc/product/14871/pil#about-medicine;

SOTYKTU UK Summary of Product Characteristics. August 2024. Available at: https://www.medicines.org.uk/emc/product/14871/smpc#about-medicine;

Chow C et al. Eur Acad Dermatol Venereol. 2015;29(7):1406–1414.

SOTYKTU® (deucravacitinib) and you

What is SOTYKTU and what is it used for?

What can I expect from treatment with SOTYKTU?

Skin clearance

Quality of life

Possible side effects

SOTYKTU^® (deucravacitinib) and you